H.R. 8729

H.R. 8729: To amend title XIX of the Social Security Act to require that diagnostic and supplemental breast examinations are furnished without cost sharing under the Medicaid program, and for other purposes.

Introduced Greg Landsman (D) HOUSE_BILL — 119th Congress
Plain English Summary

H.R. 8729 aims to amend the Social Security Act to ensure that diagnostic and supplemental breast examinations are provided to Medicaid recipients without any cost-sharing. This means that individuals on Medicaid would not have to pay out-of-pocket expenses for these important breast health services.

Positive Media Summary

Supporters of H.R. 8729 have praised the bill for promoting women's health and ensuring that low-income individuals have access to essential breast cancer screenings without financial barriers. Advocates argue that this legislation could lead to earlier detection of breast cancer, potentially saving lives and reducing overall healthcare costs in the long run.

Negative Media Summary

Critics of H.R. 8729 have raised concerns about the potential financial implications for the Medicaid program, suggesting that the bill could increase costs for taxpayers. Some opponents argue that while the intention is noble, the bill may divert resources from other critical health services within Medicaid.

Conflict of Interest Analysis Deep Analysis
3/10
Risk Level
Low
Total Donations
$0
PAC Percentage
0%
Policy Area
Health

The analysis of H.R. 8729, which aims to amend the Social Security Act regarding breast examinations under Medicaid, reveals no direct industry overlaps between the sponsor Greg Landsman's top donor industries and the bill's subject matter. The top donor industries do not appear to have a vested interest in breast health or Medicaid policy, which suggests a lower risk of conflicts of interest. However, there is notable lobbying activity in this policy area, particularly from organizations like DIRSHU INTERNATIONAL, which contributed $100,000 via MERKAVA STRATEGIES CORPORATION. While this contribution is significant, it does not directly correlate with the bill's focus on breast examinations, indicating that the risk remains low. Voters should be aware that while there is some lobbying influence, it does not seem to directly affect the sponsor's motivations for this specific legislation.

Lobbying Activity — Who's Pushing?

Organizations that lobbied on issues related to this bill's policy area.

Client Lobbying Firm Amount
DIRSHU INTERNATIONAL MERKAVA STRATEGIES CORPORATION $100,000
CEO WORKS SAUNDERS GLOBAL DIPLOMACY $45,000
KAZI IG SAUNDERS GLOBAL DIPLOMACY $15,000
SOUTHERN FOLGER CONTRACTING BBT STRATEGIES LLC $10,000
WATERFRONT GLOBAL BBT STRATEGIES LLC $5,200
DIGITALEUROPE VIVID STRATEGIES LLC undisclosed
INTERNATIONAL CHRISTIAN CHAMBER OF COMMERCE MERKAVA STRATEGIES CORPORATION undisclosed
DR. STEPHEN SOLOWAY MERKAVA STRATEGIES CORPORATION undisclosed
ONE ISRAEL FUND MERKAVA STRATEGIES CORPORATION undisclosed
HEMOGLOBIN OXYGEN THERAPEUTICS MERKAVA STRATEGIES CORPORATION undisclosed
ATAOLLAH AMINPOUR MERKAVA STRATEGIES CORPORATION undisclosed
HERSEL NEMAN MERKAVA STRATEGIES CORPORATION undisclosed
MORAD BEN NEMAN MERKAVA STRATEGIES CORPORATION undisclosed
MARK SCOTT MERKAVA STRATEGIES CORPORATION undisclosed
BORIS MINTS MERKAVA STRATEGIES CORPORATION undisclosed

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026

Sponsor's Top Donor Industries

Top industries funding Greg Landsman, ranked by total contributions.

Health Professionals $120,000,000
Individuals: $120,000,000 PACs: $0
Retired $37,500,000
Individuals: $37,500,000 PACs: $0

Source: OpenSecrets.org (Center for Responsive Politics)

TheBillRoom is free and independent. No ads, no subscriptions, no political funding. If this analysis was useful, reader support keeps it running.
Support Us